A recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer's disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.
Personalized repetitive transcranial magnetic stimulation targeting the hippocampal network improves cognitive and functional performance in early Alzheimer's.
Data from a small phase I study show significant clinical and biomarker activity of an investigational natural killer cell therapy in adults with AD, prompting a larger phase 2 trial.